{"transactions":[{"id":724978,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-29T20:08:28.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."}],"balance_after":26000,"derivative":{"exercise_price":34.09,"exercise_date":"2027-06-25","expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001198578-26-000002","document":"form4-06292026_080625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000119857826000002/form4-06292026_080625.xml","form_type":"4"}},{"id":1119003,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-09T20:07:52.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."}],"balance_after":16500,"derivative":{"exercise_price":19.53,"exercise_date":"2026-06-05","expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-25-016217","document":"form4-06092025_080645.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588925016217/form4-06092025_080645.xml","form_type":"4"}},{"id":1357989,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-20T21:02:46.000Z","date":"2024-11-18","kind":"gift","planned":false,"acquired":false,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction represents a gift transfer to an immediate family member of the reporting person who does not share the same household as the reporting person."}],"balance_after":2204,"source":{"system":"sec-edgar","filing":"0001415889-24-027329","document":"form4-11202024_091142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924027329/form4-11202024_091142.xml","form_type":"4"}},{"id":1478171,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-06-17T20:04:25.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."}],"balance_after":16500,"derivative":{"exercise_price":36.43,"exercise_date":"2025-06-13","expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-24-017141","document":"form4-06172024_080622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924017141/form4-06172024_080622.xml","form_type":"4"}},{"id":1808816,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2023-08-14T21:41:42.000Z","date":"2023-08-10","kind":"grant","planned":false,"acquired":true,"shares":66468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest 100% on the first anniversary of the grant date."}],"balance_after":66468,"derivative":{"exercise_price":1.02,"exercise_date":"2024-08-10","expiration_date":"2033-08-10","underlying":"Common Stock","underlying_shares":66468},"source":{"system":"sec-edgar","filing":"0001415889-23-012227","document":"form4-08142023_090832.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588923012227/form4-08142023_090832.xml","form_type":"4"}},{"id":1850842,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-06-20T20:09:14.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":11300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."}],"balance_after":11300,"derivative":{"exercise_price":36.87,"exercise_date":"2024-06-15","expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":11300},"source":{"system":"sec-edgar","filing":"0001415889-23-010035","document":"form4-06202023_080610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588923010035/form4-06202023_080610.xml","form_type":"4"}},{"id":2178524,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2022-08-19T20:59:31.000Z","date":"2022-08-18","kind":"grant","acquired":true,"shares":66468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest 100% on the first anniversary of the grant date."}],"balance_after":66468,"derivative":{"exercise_price":1.26,"exercise_date":"2023-08-18","expiration_date":"2032-08-18","underlying":"Common Stock","underlying_shares":66468},"source":{"system":"sec-edgar","filing":"0001415889-22-008913","document":"form4-08192022_010813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000141588922008913/form4-08192022_010813.xml","form_type":"4"}},{"id":2229172,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-17T20:06:20.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":13600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."}],"balance_after":13600,"derivative":{"exercise_price":22.48,"exercise_date":"2023-06-16","expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":13600},"source":{"system":"sec-edgar","filing":"0001415889-22-006696","document":"form4-06172022_010659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588922006696/form4-06172022_010659.xml","form_type":"4"}},{"id":2557874,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-28T16:32:40.000Z","date":"2021-09-28","kind":"purchase","acquired":true,"shares":5952,"price":4.2,"value":24998.4,"ownership":{"direct":true},"balance_after":21334,"source":{"system":"sec-edgar","filing":"0001179110-21-008955","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911021008955/edgar.xml","form_type":"4"}},{"id":2621481,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2021-07-30T23:12:50.000Z","date":"2021-07-30","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest 100% on the first anniversary of the grant date."}],"balance_after":13000,"derivative":{"exercise_price":4.97,"exercise_date":"2022-07-30","expiration_date":"2031-07-30","underlying":"Common stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001179110-21-007789","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911021007789/edgar.xml","form_type":"4"}},{"id":2662442,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-06-21T20:19:17.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."}],"balance_after":12000,"derivative":{"exercise_price":28,"exercise_date":"2022-06-17","expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001179110-21-006887","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911021006887/edgar.xml","form_type":"4"}},{"id":2855470,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-17T13:46:23.000Z","date":"2021-02-16","kind":"purchase","acquired":true,"shares":25000,"price":1,"value":25000.0,"ownership":{"direct":true},"balance_after":230716,"source":{"system":"sec-edgar","filing":"0001179110-21-001782","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911021001782/edgar.xml","form_type":"4"}},{"id":2965323,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-27T18:34:52.000Z","date":"2020-11-24","kind":"purchase","acquired":true,"shares":38774,"price":0.258,"value":10003.692,"ownership":{"direct":true},"balance_after":205716,"source":{"system":"sec-edgar","filing":"0001179110-20-011442","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911020011442/edgar.xml","form_type":"4"}},{"id":3085068,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Appreciation Right","published_at":"2020-07-10T21:30:34.000Z","date":"2020-07-09","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock appreciation rights vest 100% on the first anniversary of the grant date."}],"balance_after":125000,"derivative":{"exercise_price":0.56,"exercise_date":"2021-07-09","expiration_date":"2030-07-09","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001179110-20-008195","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911020008195/edgar.xml","form_type":"4"}},{"id":3104876,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-06-19T12:03:57.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan."}],"balance_after":11000,"derivative":{"exercise_price":10.38,"exercise_date":"2021-06-18","expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001179110-20-007588","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911020007588/edgar.xml","form_type":"4"}},{"id":3115619,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2020-06-10T11:54:53.000Z","date":"2020-06-09","kind":"purchase","acquired":true,"shares":8305,"price":3,"value":24915.0,"ownership":{"direct":true},"balance_after":12704,"source":{"system":"sec-edgar","filing":"0001179110-20-007165","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911020007165/edgar.xml","form_type":"4"}},{"id":3358979,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to purchase)","published_at":"2019-11-26T12:53:58.000Z","date":"2019-11-25","kind":"purchase","acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20."}],"balance_after":150000,"derivative":{"exercise_price":0.2,"exercise_date":"2019-11-25","expiration_date":"2024-11-25","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001179110-19-012058","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911019012058/edgar.xml","form_type":"4"}},{"id":3358978,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-26T12:53:58.000Z","date":"2019-11-25","kind":"purchase","acquired":true,"shares":150000,"price":0.2,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20."}],"balance_after":166942,"source":{"system":"sec-edgar","filing":"0001179110-19-012058","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911019012058/edgar.xml","form_type":"4"}},{"id":3405891,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to purchase)","published_at":"2019-09-26T22:22:44.000Z","date":"2019-09-25","kind":"purchase","acquired":true,"shares":1472.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock)."}],"balance_after":1472.5,"derivative":{"exercise_price":0.1067,"exercise_date":"2019-09-25","expiration_date":"2022-12-31","underlying":"Series B Convertible Preferred Stock","underlying_shares":1472.5},"source":{"system":"sec-edgar","filing":"0001179110-19-010682","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911019010682/edgar.xml","form_type":"4"}},{"id":3405890,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to purchase)","published_at":"2019-09-26T22:22:44.000Z","date":"2019-09-25","kind":"other","acquired":false,"shares":1472.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"These warrants were acquired in a public offering, by the Company, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425."},{"field":"kind","element":"transactionCoding","label":"F6","text":"In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The warrants were exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and would expire on the 18-month anniversary of the date on which the Company publicly announced through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware."}],"balance_after":0,"derivative":{"exercise_price":0.425,"exercise_date":"2018-05-01","underlying":"Series B Convertible Preferred Stock","underlying_shares":1472.5},"source":{"system":"sec-edgar","filing":"0001179110-19-010682","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911019010682/edgar.xml","form_type":"4"}},{"id":3405889,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to purchase)","published_at":"2019-09-26T22:22:44.000Z","date":"2019-09-25","kind":"purchase","acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock)."}],"balance_after":5000,"derivative":{"exercise_price":0.1067,"exercise_date":"2019-09-25","expiration_date":"2022-12-31","underlying":"Series A Convertible Preferred Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-19-010682","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911019010682/edgar.xml","form_type":"4"}},{"id":3405888,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to purchase)","published_at":"2019-09-26T22:22:44.000Z","date":"2019-09-25","kind":"other","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These warrants were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01."},{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The warrants were exercisable immediately at an exercise price of $1.01 per 0.1 share of Series A Convertible Preferred Stock and would expire on the later of (i) the one-year anniversary of the date on which theCompany publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which the Company publically releases certain topline results of the INSPIRE Pivotal phase 3 trial that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019."}],"balance_after":0,"derivative":{"exercise_price":1.01,"exercise_date":"2018-02-12","underlying":"Series A Convertible Preferred Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-19-010682","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911019010682/edgar.xml","form_type":"4"}},{"id":3405887,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-26T22:22:44.000Z","date":"2019-09-25","kind":"purchase","acquired":true,"shares":7260,"price":1.6,"value":11616.0,"ownership":{"direct":true},"balance_after":16942,"source":{"system":"sec-edgar","filing":"0001179110-19-010682","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911019010682/edgar.xml","form_type":"4"}},{"id":3454400,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2019-07-29T21:25:37.000Z","date":"2019-07-26","kind":"grant","acquired":true,"shares":5833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest 100% on the first anniversary of the grant date."}],"balance_after":5833,"derivative":{"exercise_price":3.39,"exercise_date":"2020-07-26","expiration_date":"2029-07-26","underlying":"Common Stock","underlying_shares":5833},"source":{"system":"sec-edgar","filing":"0001179110-19-008868","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911019008868/edgar.xml","form_type":"4"}},{"id":3483512,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-06-20T20:27:08.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan."}],"balance_after":4500,"derivative":{"exercise_price":2.78,"exercise_date":"2020-06-19","expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-19-007971","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911019007971/edgar.xml","form_type":"4"}},{"id":3832267,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2018-08-28T11:34:34.000Z","date":"2018-08-24","kind":"purchase","acquired":true,"shares":40000,"price":0.48,"value":19200.0,"ownership":{"direct":true},"balance_after":65997,"source":{"system":"sec-edgar","filing":"0001179110-18-010938","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911018010938/edgar.xml","form_type":"4"}},{"id":3859174,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2018-07-30T21:32:53.000Z","date":"2018-07-26","kind":"grant","acquired":true,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest 100% on the first anniversary of the grant date."}],"balance_after":87500,"derivative":{"exercise_price":0.46,"exercise_date":"2019-07-26","expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001179110-18-010015","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911018010015/edgar.xml","form_type":"4"}},{"id":3893266,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-06-15T11:34:43.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan."}],"balance_after":67000,"derivative":{"exercise_price":0.6011,"exercise_date":"2019-06-13","expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001179110-18-008561","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911018008561/edgar.xml","form_type":"4"}},{"id":3952245,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to purchase)","published_at":"2018-05-01T22:28:56.000Z","date":"2018-04-27","kind":"purchase","acquired":true,"shares":58900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware."}],"balance_after":58900,"derivative":{"exercise_price":0.425,"exercise_date":"2018-04-27","underlying":"Series B Convertible Prefered Stock","underlying_shares":1472.5},"source":{"system":"sec-edgar","filing":"0001179110-18-006013","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911018006013/edgar.xml","form_type":"4"}},{"id":3952244,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-01T22:28:56.000Z","date":"2018-04-27","kind":"purchase","acquired":true,"shares":58900,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315)."}],"balance_after":145221,"source":{"system":"sec-edgar","filing":"0001179110-18-006013","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911018006013/edgar.xml","form_type":"4"}},{"id":4066304,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to purchase)","published_at":"2018-02-12T22:20:23.000Z","date":"2018-02-08","kind":"purchase","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-222374)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The warrants are exercisable immediately at an exercise price of $1.01 per 0.1 share of Series A Convertible Preferred Stock and will expire on the later of (i) the one-year anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which the Company publically releases certain topline results of the INSPIRE Pivotal phase 3 trial that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk  and (B) December 31, 2019."}],"balance_after":50000,"derivative":{"exercise_price":1.01,"exercise_date":"2018-02-08","underlying":"Series A Convertible Preferred Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-18-001967","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911018001967/edgar.xml","form_type":"4"}},{"id":4066303,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-12T22:20:23.000Z","date":"2018-02-08","kind":"purchase","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-222374)."}],"balance_after":86321,"source":{"system":"sec-edgar","filing":"0001179110-18-001967","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911018001967/edgar.xml","form_type":"4"}},{"id":4280109,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-06-16T13:32:04.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Such option vests in three equal annual installments beginning June 15, 2018."}],"balance_after":15000,"derivative":{"exercise_price":2.32,"exercise_date":"2018-06-15","expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001179110-17-009168","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911017009168/edgar.xml","form_type":"4"}},{"id":4280108,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2017-06-16T13:32:04.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions."}],"balance_after":25997,"source":{"system":"sec-edgar","filing":"0001179110-17-009168","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911017009168/edgar.xml","form_type":"4"}},{"id":4284019,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2017-06-13T21:07:12.000Z","date":"2017-06-12","kind":"grant","acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over one year from the grant date in 12 equal monthly installments."}],"balance_after":1500,"derivative":{"exercise_price":1.94,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001179110-17-008998","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911017008998/edgar.xml","form_type":"4"}},{"id":4342260,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-28T19:04:22.000Z","date":"2017-04-26","kind":"purchase","acquired":true,"shares":11906,"price":2.1,"value":25002.6,"ownership":{"direct":true},"balance_after":36321,"source":{"system":"sec-edgar","filing":"0001179110-17-006248","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000117911017006248/edgar.xml","form_type":"4"}},{"id":4416044,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35022,"kind":"person","name":"MARINO JAMES J","position":1,"cik":"0001198578","reported_name":"MARINO JAMES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-03-01T21:33:09.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the total amount of shares subject to the Option vests on March 1, 2018."}],"balance_after":8000,"derivative":{"exercise_price":3.56,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001179110-17-003487","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000117911017003487/edgar.xml","form_type":"4"}}]}